• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
drug pricing
August 21, 2020 by Global Pricing Innovations (GPI)
Netherlands new IRP rule to come into effect 1st October 2020

By Musa Kureshy, Business Development Manager The impact of COVID-19 has been felt by every country and industry and the Netherlands was no exception. COVID-19 impactied drug manufacturing in China leading to it coming to a stand still and India implemented export restrictions…

March 3, 2020 by Global Pricing Innovations (GPI)
Canada moved further to tackle high drug prices as Patented Medicines Prices Review Board (“PMPRB”) released new draft Guidelines for consultation

By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…

GPI in Canada
How will Pfizer's discounted biosimilars affect Roche?
February 7, 2020 by Global Pricing Innovations (GPI)
Pfizer’s newest range of biosimilars are set to significantly undercut Roche’s ‘best-selling’ Avastin, Herceptin, and Rituxan on pricing. What will be the impact on Roche’s market share?

Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…

January 22, 2020 by Global Pricing Innovations (GPI)
Global Pricing Innovations announces relocation of London Head office

London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…

New Head Office Location Announcement
Global Pricing Innovations Pharmaceutical Industry
January 2, 2020 by Global Pricing Innovations (GPI)
Pharmaceutical industry offers large medicine discounts in the Philippines

In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…

October 25, 2019 by Global Pricing Innovations (GPI)
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs

Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…

Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs
GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

October 18, 2019 by Global Pricing Innovations (GPI)
Novartis’s gene therapy Luxturna receives ‘considerable added benefit’ in Germany

  Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…

Novartis building
October 1, 2019 by Global Pricing Innovations (GPI)
Pharma price and access pioneers, Global Pricing Innovations (GPI), continue growth with the strategic expansion to Cambridge, UK.

New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support.   London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…

September 25, 2019 by Global Pricing Innovations (GPI)
What the Beneluxa Group is aiming for next

BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…

What the Beneluxa Group is aiming for next
September 23, 2019 by Global Pricing Innovations (GPI)
With the Updated Stability Programme 2019-2022, Spanish government reinforces healthcare budget control measures

In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…

August 30, 2019 by Global Pricing Innovations (GPI)
Roche’s Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe.

  Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…

August 27, 2019 by Global Pricing Innovations (GPI)
Italy’s drug pricing reform in trouble as Prime Minister Conte resigns

  On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…

August 23, 2019 by Global Pricing Innovations (GPI)
US Government is considering introduction of International Reference Pricing

President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…

August 19, 2019 by Global Pricing Innovations (GPI)
Canada finalises new regulations to tackle high drug prices

  Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…

June 19, 2019 by Global Pricing Innovations (GPI)
The new Pricing System in Russia will lead to price decreases for many medicines

  Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…

June 10, 2019 by Global Pricing Innovations (GPI)
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement?

  Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…

June 4, 2019 by Global Pricing Innovations (GPI)
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation.

Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.

June 3, 2019 by Global Pricing Innovations (GPI)
Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA

  The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…

May 15, 2019 by Global Pricing Innovations (GPI)
New set of rules regulating medicine prices in Kazakhstan

  New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…

May 7, 2019 by Global Pricing Innovations (GPI)
Malaysian authorities approve the introduction of IRP

  Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…

April 18, 2019 by Global Pricing Innovations (GPI)
New IRP rule introduced in Greece

International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…

April 8, 2019 by Global Pricing Innovations (GPI)
Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices

By Alexandros Soumalevris, GPI     Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…

March 5, 2019 by Global Pricing Innovations (GPI)
Pricing pharmaceuticals: The transition from prospective qualitative research to predictive data analytics

By Alexandrosz Czira and Henrike Granzow Finding the right price in a cost-constrained global healthcare environment Needless to reiterate that costs of healthcare continue to increase. Some of the main drivers behind this trend are the development costs of novel and efficacious medicines…

May 23, 2018 by Global Pricing Innovations (GPI)
Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme

GPI LEAP creates a clear vision for the most ambitious talent by inspiring individuals from diverse backgrounds to come together, grow and succeed in an innovative and dynamic team. We are passionate about growing and developing a world-class, high-performing team of experts through…

January 5, 2018 by Global Pricing Innovations (GPI)
New Year, New Start – GPI are hiring

Global Pricing Innovations are hiring! We are looking for pharmacists and project managers to join our expanding London based team. Please contact us for further information or email your resume to careers@globalpricing.com.

December 22, 2017 by Global Pricing Innovations (GPI)
Season's Greetings from GPI
September 16, 2017 by Global Pricing Innovations (GPI)
Partners4Access and Global Pricing Innovations open new London Headquarters to complement innovative thinking and disruptive technology growth

Partners4Access (P4A), the orphan drug specialists, and Global Pricing Innovations (GPI), the pricing experts, are moving to larger premises in central London to account for expansion and growth. Aligned to their innovative thinking and approach with their pharmaceutical clients, the new premises are…

Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121